BioSpace News Archive

Business

Senti Biosciences Brings on Curt Herberts to Help Build New Partnerships

South San Francisco-based Senti Biosciences is getting a new Chief Financial Officer and Chief Business Officer. Former Sangamo Therapeutics Senior Vice President and Chief Business Officer Curt Herberts will join Senti later this month.

June 6, 2018
·
1 min read
·
Don McCormick
Genetown

Biogen Pays Alkermes $50 Million Milestone for MS Drug

Alkermes, received a $50 million milestone payment from Biogen. The payment occurred after Biogen reviewed preliminary gastrointestinal tolerability data from an ongoing Phase III clinical trial for MS.

June 6, 2018
·
3 min read
·
Mark Terry
Biotech Beach

Metacrine Closes $65 Million Series C Round

Metracrine, based in San Diego, completed a Series C financing round worth $65 million.

June 6, 2018
·
3 min read
·
Mark Terry
Business

Le-Vel Celebrates Largest Month In Company History

Nutritional innovator shatters sales records in May

June 6, 2018
·
2 min read
BioMidwest

2018 AIDS Walk Greater Dayton

Community Comes Together to Help Support HIV Prevention & Treatment

June 6, 2018
·
2 min read
Business

Biological Industries USA Adds Vitronectin XF™ to its Stem Cell Portfolio Through Agreement with Primorigen Biosciences, Inc.

Biological Industries USA and Primorigen Biosciences, Inc. announce a strategic partnership for non-exclusive worldwide distribution of Primorigen’s proprietary Vitronectin XF™ protein matrix for stem cell culture.

June 6, 2018
·
3 min read
BioCapital

Sirnaomics Closed Series C1 Financing of US$25 Million and Expands Clinical Programs of Anti-Fibrosis and Anti-Cancer RNAi Therapeutics

Sirnaomics, Inc. announces that it has closed Series C1 financing of US$25 Million (RMB?160 Million).

June 6, 2018
·
3 min read
Deals

Viking Therapeutics Announces Proposed Public Offering of Common Stock June 6, 2018

Viking Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

June 6, 2018
·
5 min read
Drug Development

Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy

Proteostasis Therapeutics, Inc. announced positive results from the Company’s ongoing 14-day dosing study of PTI-801 in CF patients on background Orkambi® (lumacaftor/ivacaftor) therapy.

June 6, 2018
·
13 min read
Genetown

Vertex to Present at the Goldman Sachs Healthcare Conference on June 13

Vertex Pharmaceuticals Incorporated announced that management will present at the Goldman Sachs Healthcare Conference

June 6, 2018
·
1 min read